Stephanie Holland

News

FDA Approves Repotrectinib for Patients With Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer

11/17/2023

Based on results from the TRIDENT-1 study, the FDA has approved repotrectinib for patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer.

Based on results from the...

11/17/2023

Oncology

Conference Coverage

Navitoclax Added to Dabrafenib-Trametinib Improved Response, Survival Among Patients With BRAF-Mutant Metastatic Melanoma

06/12/2023

Stephanie Holland ;

Findings of a phase 2 study presented at the 2023 ASCO Annual Meeting demonstrated the addition of navitoclax to dabrafenib and trametinib improved response and survival outcomes for patients with BRAF-mutant metastatic melanoma.

Findings of a phase 2 study...

06/12/2023

Oncology

News

Amivantamab Plus Chemotherapy Provides PFS Benefit in EGFR-Mutated NSCLC

09/11/2023

Stephanie Holland ;

According to Janssen Pharmaceutical Companies of Johnson & Johnson, amivantamab with or without lazertinib plus chemotherapy significantly improves progression-free survival among patients with EGFR-mutated NSCLC.

According to Janssen...

09/11/2023

Oncology

News

Neoadjuvant Pembrolizumab Plus Carboplatin and Docetaxel Improved Response, Survival Rates Among Patients With Triple-Negative Breast Cancer

01/11/2024

Stephanie Holland ;

According to clinical and biomarker results from the phase 2 NeoPACT trial, neoadjuvant pembrolizumab plus carboplatin and docetaxel improved pathological complete response and 3-year event-free survival rates among patients with...

According to clinical and...

01/11/2024

Oncology

News

Zipalertinib Displayed Promising Preliminary Antitumor Activity Among Patients With EGFR-Mutant NSCLC

07/24/2023

Stephanie Holland ;

According to results of a phase 1/2a study, zipalertinib demonstrated promising preliminary antitumor activity with acceptable safety among patients with heavily pretreated EGFR ex20ins-mutant NSCLC.

According to results of a phase...

07/24/2023

Oncology

Conference Coverage

Inavolisib, Palbociclib And Fulvestrant As Potential New Standard of Care for Patients With PIK3CA-Mutated, HR-Positive, HER2-Negative Breast Cancer

12/08/2023

Stephanie Holland ;

According to primary analysis results from the phase 3 INAVO120 trial, the addition of inavolisib to palbociclib plus fulvestrant significantly improved investigator-assessed progression-free survival in PIK3CA-mutated, hormone...

According to primary analysis...

12/08/2023

Oncology

News

Hyperthermic Intraperitoneal Chemotherapy Plus Interval Cytoreductive Surgery Significantly Improved Long-Term Survival Outcomes in Advanced Ovarian Cancer

10/12/2023

Stephanie Holland ;

According to updated survival results from the phase 3 OVHIPEC-1 trial, the addition of hyperthermic intraperitoneal chemotherapy to interval cytoreductive surgery significantly improved long-term progression-free survival and overall...

According to updated survival...

10/12/2023

Oncology

News

Tipifarnib for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma With HRAS Mutations

10/31/2023

Stephanie Holland ;

According to results from AIN-HN study, tipifarnib is safe, tolerable, and demonstrated anti-tumor activity n later-line settings among patients with HRAS-mutated recurrent or metastatic head and neck squamous cell carcinoma who had received...

According to results from AIN-HN...

10/31/2023

Oncology

News

FDA Approves Pralsetinib for Locally Advanced, Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

08/10/2023

Stephanie Holland ;

Based on follow-up data from the ARROW trial, the FDA has approved pralsetinib for patients with locally advanced or metastatic RET fusion-positive non-small cell lung cancer.

Based on follow-up data from the...

08/10/2023

Oncology

News

Durvalumab Plus Concurrent Radiotherapy for Unresectable, Advanced, PD-L1-Positive NSCLC

11/15/2023

Stephanie Holland ;

Results from the phase 2 DOLPHIN study found that durvalumab plus concurrent radiotherapy followed by maintenance durvalumab is an effective and safe treatment option for patients with unresectable, advanced, PD-L1-positive non-small cell...

Results from the phase 2 DOLPHIN...

11/15/2023

Oncology